What is Arbor Biotechnologies?
Arbor Biotechnologies, based in Cambridge, MA, is at the forefront of developing next-generation gene editing therapeutics designed to combat a broad spectrum of genetic conditions, from ultra-rare diseases to more common genetic ailments. The company has developed a proprietary suite of optimized gene editors capable of diverse editing modalities, including gene knockout, excisions, reverse transcriptase editing, and large gene insertion. This advanced technology surpasses the limitations of earlier gene editing methods, enabling access to novel gene targets and supporting a robust pipeline of first-in-class assets. Arbor's lead program, ABO-101, is currently in clinical development for the treatment of primary hyperoxaluria type 1, with ongoing research and development efforts concentrated on genomic diseases affecting the liver and central nervous system where functional cures are currently lacking.
How much funding has Arbor Biotechnologies raised?
Arbor Biotechnologies has raised a total of $289.3M across 3 funding rounds:
Debt
$350K
Series B
$215M
Series C
$73.9M
Debt (2020): $350K with participation from PPP
Series B (2021): $215M led by Temasek, Ally Bridge Group, and Piper Sandler
Series C (2025): $73.9M supported by Temasek, ArrowMark Partners, Vertex Pharmaceuticals, Tcgx, Ally Bridge Group, Abrdn Japan Equity Fund, Piper Sandler Heartland Summit, Revelation Partners, ARCH VENTURE PARTNERS, Deep Track Capital, and Surveyor Capital
Key Investors in Arbor Biotechnologies
Temasek
Temasek is a global investment company headquartered in Singapore, known for its generational investment approach and focus on making a difference with tomorrow in mind.
Ally Bridge Group
Ally Bridge Group is a global healthcare investment management firm specializing in high-impact life science innovation, managing over $6 billion in transactions and focusing on both private equity and public equity strategies.
ArrowMark Partners
ArrowMark Partners is an employee-owned asset manager established in 2007, with specialized expertise in alternative credit and growth equity asset classes, primarily serving investment companies.
What's next for Arbor Biotechnologies?
The substantial enterprise-level funding and major strategic investment indicate Arbor Biotechnologies is poised for significant expansion and advancement of its therapeutic pipeline. This capital infusion is expected to accelerate the clinical development of ABO-101 and further research into other genomic diseases. The company's focus on innovative gene editing technologies positions it for continued growth and potential breakthroughs in addressing unmet medical needs in genetic disorders.
See full Arbor Biotechnologies company page
